Matching-adjusted indirect comparison of selpercatinib and pralsetinib in <i>RET</i> fusion–positive non–small cell lung cancer

Selpercatinib and pralsetinib are approved for RET-rearranged non – small cell lung cancer. Efficacy and safety were compared using matching-adjusted indirect comparison. Median progression-free survival (PFS) was 22.1 and 13.3 months for selpercatinib and pralsetinib, respectively (HR = 0.67; 95% CI, 0.53–0.85). Objective response rate was 64.5% and 65.8%, and disease control rate was 92.1% and 90.4%, respectively. Median overall survival was not reached for selpercatinib and 43.9 months for pralsetinib (HR = 0.81; 95% CI, 0.60–1.09). Grade ≥ 3 treatment-related adverse events (TRAEs) were reported in 39.3% and 62.6% of patients, with discontinuations due to TRAEs in 3.6% and 10.0% of patients, respectively. Outcomes were similar; however, PFS was significantly prolonged with selpercatinib, with fewer grade ≥ 3 TRAEs.